Evidence map›Paper›PMID 28049736›Full record

Trial reportClinical science (London, England : 1979)2017

GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.

Emilie Pastel, Laura J McCulloch, Rebecca Ward, Shivam Joshi, Kim M Gooding, Angela C Shore, Katarina Kos

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical science (London, England : 1979), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01740921. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01740921 nacompleted

Does Glucagon-like Polypeptide 1 Improve Vascular Function and Inflammation?

Ran2011Enrolled39Registered outcomes6Posted comparisons0ConditionsType 2 DiabetesArmsAspirin, diet, liraglutide
Open the trial in the graph
NCT04122716 phase4unknown status

Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial

Ran2016Enrolled215Registered outcomes28Posted comparisons0ConditionsObesityArmsExercise, liraglutide
PMID 23186644PMID 26132939PMID 26284720PMID 30052921PMID 27295427PMID 27633186PMID 25287751PMID 23812094PMID 26916363PMID 11234459PMID 11684524PMID 11812755other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Achieving equitable access to incretin-based therapies in cardiovascular care.American heart journal plus : cardiology research and practice · 2024
    Article
  9. Article
  10. Metaflammation in obesity and its therapeutic targeting.Science translational medicine · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Emilie PastelDiabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Laura J McCullochDiabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Rebecca WardDiabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Shivam JoshiDiabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Kim M GoodingDiabetes and Vascular Medicine, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Angela C ShoreDiabetes and Vascular Medicine, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Katarina KosDiabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K. k.kos@exeter.ac.uk.
University of Exeter · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucagon-like peptide-1 (GLP-1) analogues aid weight loss that improves obesity-associated adipose tissue (AT) dysfunction. GLP-1 treatment may however also directly influence AT that expresses the GLP-1 receptor (GLP-1R). The present study aimed to assess the impact of GLP-1 analogue treatment on subcutaneous AT (SCAT) inflammatory and fibrotic responses, compared with weight loss by calorie reduction (control). Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (

Indexed as

AdiponectinAdipose TissueAgedDiabetes Mellitus, Type 2Extracellular MatrixGlucagon-Like Peptide 1HumansHypoglycemic AgentsInflammationLeptinLiraglutideMaleMiddle AgedObesityAdiponectinGlucagon-Like Peptide 1Hypoglycemic AgentsLeptinLiraglutideadipose tissue fibrosisglucagon-like peptide-1 (GLP-1) analogueLiraglutideobesityType 2 diabetes

Identifiers

PMID28049736
OpenAlexW2567189085

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.